Yeovil dental hygienist named finalist for Ms Great Britain 2025
Rafina O'Brien is using her platform to advocate for oral health, support charitable causes, and highlight the Somerset community.
Her 'When She Smiles' campaign centres on women's oral health, a frequently neglected issue.
She raises awareness of how hormonal changes during puberty, pregnancy, and menopause can harm gum and bone health, potentially resulting in severe consequences like low birth weight and premature birth.
Ms O'Brien aims to educate women about the importance of taking charge of their dental health through community discussions and online initiatives.
She said: "I believe oral health is about much more than just teeth.
"It's about confidence, wellbeing, dignity, and overall health — and everyone deserves access to that, no matter their background."
She also works with Dentaid, a charity that operates mobile dental units and clinics for people experiencing homelessness.
Ms O'Brien volunteers at these clinics, teaches oral hygiene practices to schools and community groups, and organises fundraising events, such as recently completing three ultra-marathons in three months.
She also served as the first dental hygienist on the world tour of HMS Queen Elizabeth in 2021, as seen in the BBC documentary, The Warship: Tour of Duty.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
2 hours ago
- Yahoo
These medications could save thousands of lives – but doctors aren't prescribing them
In 2021, varenicline, the most effective single drug for quitting smoking, was withdrawn from the market in the UK because impurities were found at greater levels than is considered safe. Rapidly, varenicline (then sold under its brand names, Champix and Chantix) became unavailable. This was a disaster for public health. Research from University College London estimated that varenicline being unavailable resulted in about 1,890 more avoidable deaths each year because fewer people were successfully quitting smoking. But there was hope. Cytisine (also known as cytisinicline), a naturally occurring plant-based product that had been used for decades in Eastern Europe, and more recently to great effect elsewhere in the world, was licensed in the UK and made available from January 2024. Even so, there was an extended period when neither were available to people trying to quit smoking in the UK (and in other countries, too). But in the UK at least, things were looking up. Based on a limited but growing body of evidence, cytisine probably works as well as varenicline at helping people quit smoking, and it may be better tolerated with fewer side effects. It may also appeal to more smokers who may want to use a natural product rather than a drug designed in a lab. So, with varenicline withdrawn and a similarly effective treatment available, we should have seen lives saved as people who would have taken varenicline were encouraged to try cytisine instead. Why isn't anyone prescribing it? This didn't happen. Cytisine – despite now being licensed and available in the UK – is still shockingly underused. Since January 2024, only 0.2% of people trying to quit smoking have used it (the same proportion that used it in 2018, when it wasn't even officially available in the UK). Official NHS data from people accessing stop-smoking services in England confirm that only 0.7% were prescribed cytisine in 2024. So why is this? High-profile trials continue to show cytisine's effectiveness for quitting smoking (and even for quitting vaping). Maybe cytisine's relatively complex dosing schedule puts people off. Cytisine starts with six pills a day (one every two hours) and gradually tapers off over a few weeks: more confusing and less convenient than one-a-day varenicline. Another possibility is that the public's attention has shifted. With so much focus in recent years on vaping as a smoking cessation aid, prescription drugs for smoking cessation may have fallen off the radar. It could also be that GPs are reluctant to prescribe cytisine because of its cost and the assumption that local authorities should pay for it, not primary care. While it was once hoped that due to its low-cost availability in Eastern Europe, it would become the 'aspirin of smoking cessation drugs', the licensed product in the UK is now as or more expensive than other drugs. But the simplest explanation is probably the most accurate: not enough people know about cytisine. People who smoke, GPs, pharmacists and even stop-smoking services may not know it's an option. And if no one is talking about it, no one is prescribing it. And even if they do know about it, there may be a lack of confidence in using or prescribing it because it is a new drug. That's a problem. The UK government has made the shift from treating illness to preventing it a central part of its health strategy. Smoking remains the leading cause of preventable death in the country and the world. If we're serious about prevention, then effective smoking cessation support must be top of the agenda. Now, varenicline is available again (without its brand names and reformulated to remove the impurities). This is welcome news, but only 1.1% of past-year smokers reported using varenicline. That's only a quarter of the number from before its withdrawal. This raises an important question: should we return to prescribing varenicline by default, or is it time to consider cytisine as a first-line treatment? Researchers are continuing to learn more about cytisine, but as the evidence in favour of cytisine grows, maybe it needs a PR campaign for both prescribers and people who smoke. None of this is to say that cytisine is a miracle cure, or that it will work for everyone. But that's true of every way to help people quit smoking. Quitting smoking is hard, and people trying to quit need more options, not fewer, and those options need to be visible and accessible. Jonathan Livingstone-Banks is a Lecturer & Senior Researcher in Evidence-Based Healthcare at the University of Oxford. Dimitra Kale is a Senior Research Fellow in Health Psychology at UCL. Lion Shahab is a Professor in Health Psychology at UCL. This article is republished from The Conversation under a Creative Commons license. Read the original article.
Yahoo
4 hours ago
- Yahoo
The disease which takes 3.5 years to diagnose after symptoms start
A disease that affects almost one million people in the UK takes around 3.5 years to diagnose, researchers have found. Dementia sufferers have to wait a lengthy time from the onset of symptoms to an official diagnosis. And some people with early-onset dementia have an even longer wait of just over four years. A new study by UCL researchers is the first systematic review and meta-analysis of global evidence examining time to diagnosis in dementia. READ MORE: Learner drivers 'struggling to pass' as three Midland test centres among the UK's toughest The researchers reviewed data from 13 previously published studies which took place in Europe, US, Australia and China, reporting data on 30,257 participants. The study, published in the International Journal of Geriatric Psychiatry, investigated the average interval between symptom onset rated by patients or family carers using interviews or medical records to the final diagnosis of dementia. Lead author, Dr Vasiliki Orgeta, said: "Timely diagnosis of dementia remains a major global challenge, shaped by a complex set of factors, and specific healthcare strategies are urgently needed to improve it. "Other studies estimate that only 50-65% of cases are ever diagnosed in high-income countries, with many countries having even lower diagnostic rates. 'Timely diagnosis can improve access to treatments and for some people prolong the time living with mild dementia before symptoms worsen.' In a pooled meta-analysis of 10 of the included studies, the researchers found that it typically takes 3.5 years from the first alert of symptoms to a patient receiving a diagnosis of dementia, or 4.1 years for those with early-onset dementia, with some groups more likely to experience longer delays, a spokesperson for UCL said. They found that younger age at onset and having frontotemporal dementia were both linked to longer time to diagnosis. While data on racial disparities was limited, one of the studies reviewed found that black patients tended to experience a longer delay before diagnosis. Dr Orgeta said: 'Our work highlights the need for a clear conceptual framework on time to diagnosis in dementia, developed in collaboration with people with dementia, their carers, and supporters.' Dr Phuong Leung (UCL Division of Psychiatry) said: 'Symptoms of dementia are often mistaken for normal ageing, while fear, stigma, and low public awareness can discourage people from seeking help.' Professor Rafael Del-Pino-Casado, of the University of Jaén, Spain, said: 'Within healthcare systems, inconsistent referral pathways, limited access to specialists, and under-resourced memory clinics can create further delays. For some, language differences or a lack of culturally appropriate assessment tools can make access to timely diagnosis even harder.' Dr Orgeta added: 'To speed up dementia diagnosis, we need action on multiple fronts. Public awareness campaigns can help improve understanding of early symptoms and reduce stigma, encouraging people to seek help sooner. "Clinician training is critical to improve early recognition and referral, along with access to early intervention and individualised support so that people with dementia and their families can get the help they need.' The NHS lists common early symptoms of dementia as: memory loss difficulty concentrating finding it hard to carry out familiar daily tasks, such as getting confused over the correct change when shopping struggling to follow a conversation or find the right word being confused about time and place mood changes
Yahoo
8 hours ago
- Yahoo
UMass Amherst marmoset monkey lab that drew PETA's ire closes
AMHERST — A researcher whose controversial use of marmoset monkeys to unlock the secrets of Alzheimer's, aging and women's health drew the fury of PETA has closed her lab at the University of Massachusetts Amherst. In a message posted to her own website, Agnès Lacreuse says caring for primates requires top-quality infrastructure and resources. She is grateful to the National Institutes of Health and others for more than $6 million in federal funding. 'However, current efforts to destroy science and slash research funding undermine my ability to continue support for nonhuman primate research at UMass,' she said. The lab is finishing up a research project concerning the topic of breast cancer. 'Above all, my heart goes out to each one of the beloved monkeys who helped advance scientific knowledge and improve the lives of humans and other animals,' she said. The University of Massachusetts released a written statement: 'The lab, whose work has been dedicated to studies that advance the knowledge of the aging process with a focus on Alzheimer's disease and women's health (including breast cancer treatments), recently completed NIH grant-funded research using non-human primates. The funded experiments ended as planned, within the scheduled end of the grant.' PETA, People for the Ethical Treatment of Animals, declared victory in a news release. 'We were determined to close this laboratory and end the torture of these tiny monkeys, and we did,' says PETA Senior Vice President Kathy Guillermo. 'Lacreuse's reign of terror is over.' PETA described how Lacreuse's laboratory staff drilled holes in marmosets' skulls to implant electrodes, cut into their necks and threaded wires through their bodies. Stories by Jim Kinney Sports betting brought trouble for gamblers, not jobs for Mass., UMass research finds After word of potential Mercy sale, Baystate CEO reassures staff but points to nondisclosure, confidentiality Pridelands on Main St., outdoor beer garden funded through ARPA, drawing crowds Read the original article on MassLive. Solve the daily Crossword
